Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The parents of Travis and Jason Kelce went all out in their Chiefs gear, wearing her son's jersey number proudly ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Citadel has taken a short position worth 305 million pounds ($384.5 million) in GSK stock, representing a 0.51% stake, ...

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover set to lift by between 3% and 5%. It added that it expects further growth to be boosted by its strong ...

and GSK has to prove its drug development pipeline is packed with new blockbuster treatments. “An increased dividend and the launch of a first major share buyback in more than a decade suggest ...

still linger, and GSK has to prove its drug development pipeline is packed with new blockbuster treatments.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.